Showing 7191-7200 of 9383 results for "".
- FDA Extends Action Date For Tofacitinib New Drug Application By Three Monthshttps://practicaldermatology.com/news/20120824-us_food_and_drug_administration_extends_action_date_for_tofacitinib_new_drug_application_by_three_months/2459748/
- HHS Announces Next Steps To Promote Use Of Electronic Health Recordshttps://practicaldermatology.com/news/20120823-hhs_announces_next_steps_to_promote_use_of_electronic_health_records/2459749/Health and Human Services (HHS) Secretary Kathleen Sebelius
- New App Helps Physicians and Patients Take Control of Contact Dermatitishttps://practicaldermatology.com/news/20120820-new_app_helps_physicians_and_patients_take_control_of_contact_dermatitis/2459751/
- Low Cancer Risk Associated with UVA Nail Lampshttps://practicaldermatology.com/news/20120720-low_cancer_risk_associated_with_uva_nail_lamps/2459767/UVA lamps used for curing gel nails pose a very low risk for development of squamous cell carcinoma (SCC) on the dorsum of hands, new research suggests. (Br J Dermatol, E-pub). In fact, researchers say that only one woman in tens of thousands using UVA lamps over a number of years will develop SCC a
- Interactive Education Resource for Residents Now Availablehttps://practicaldermatology.com/news/20120716-interactive_education_resource_for_residents_now_available/2459772/
- Leading Melanoma Groups Unveil New Campaign Aimed at Menhttps://practicaldermatology.com/news/20120515-leading_melanoma_groups_unveil_new_campaign_aimed_at_men/2459800/
- Health Canada Approves BMS' Yervoy forhttps://practicaldermatology.com/news/20120208-health_canada_approves_bms_yervoy_for/2459870/
- FDA Expands Dupixent CSU Indication to Children as Young as 2 Yearshttps://practicaldermatology.com/news/dupixent-approval-expanded-to-include-children-as-young-as-2-years-with-csu/2487479/The US Food and Drug Administration (FDA) has expanded the indication for Dupixent (dupilumab; Sanofi and Regeneron) to include pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. The label expansion, according
- Comparative Study Finds No Significant Melanoma Mortality Reduction From German Screening Initiativehttps://practicaldermatology.com/news/comparative-study-finds-no-significant-melanoma-mortality-reduction-from-german-screening-initiative/2487471/A study of a German nationwide skin cancer screening (SCS) program showed reduced melanoma mortality compared with neighboring European countries that do not have population-based screening programs. Germany launched its nationwide SCS program in 2008, which included adults aged 35 years a
- Review: Emerging Therapies Expand Options for Patients With Genodermatoseshttps://practicaldermatology.com/news/review-emerging-therapies-expand-options-for-patients-with-genodermatoses/2487464/A new review published in the Journal of Drugs in Dermatology spotlighted recent advances in the diagnosis, classification, and treatment of several common genodermatoses, incl